Communiqués HeartSciences Inc.

Actions

HSCS

US42254E3027

Equipement et technologie médicale avancés

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/07/2026			Varia. 5j.	Varia. 1 janv.
2,560 ^USD	-2,29 %		-6,23 %	-17,15 %

23/06	Principales hausses de la mi-journée	MT
23/06	HeartSciences fusionne avec la plateforme de minage d'actifs numériques Fortitude ; le titre s'envole en avant-Bourse	MT

Communiqués

23/06	Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets	BU
11/06	European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents	AQ
02/06	HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm	AQ
19/05	HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network	AQ
05/05	HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™	AQ
14/04	HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting	AQ
25/03	HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category	AQ
24/03	HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings	AQ
16/03	HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update	AQ
05/02	University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center	AQ
30/01	Cibolo Health Designates HeartSciences MyoVista Insights as Endorsed ECG Management Platform for Network of 123 Independent Hospitals	AQ
29/01	Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals	AQ
15/12	HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update	AQ
15/12	HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device	AQ
11/12	HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1	AQ
11/09/25	HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results	AQ
15/08/25	HeartSciences Announces Conference Participation and Investor Webinar	AQ
28/07/25	HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results	AQ
24/07/25	HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results	AQ
04/06/25	HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis	AQ
04/06/25	Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences Patent Portfolio and IP Value	AQ
03/06/25	Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value	AQ
29/05/25	HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone	AQ
20/05/25	HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025	AQ
08/05/25	HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson	AQ